The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,673.00
Bid: 1,674.00
Ask: 1,675.00
Change: 3.00 (0.18%)
Spread: 1.00 (0.06%)
Open: 1,661.50
High: 1,679.50
Low: 1,658.50
Prev. Close: 1,670.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

Fri, 29th Dec 2023 13:01

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

The FTSE 100 index closed up 10.50 points, 0.1%, at 7,733.24. The FTSE 250 ended down 29.53 points, 0.2%, at 19,689.63 and the AIM All-Share closed down 0.34 of a point at 763.32.

The Cboe UK 100 ended up 0.2% at 772.47, the Cboe UK 250 closed down 0.1% at 17,163.49, and the Cboe Small Companies ended up 0.7% at 14,992.05.

At the time of the early London market close, the CAC 40 in Paris was up 0.4%, while the DAX 40 in Frankfurt was up 0.3%, on track to add 15% and 19% respectively this year.

"The UK stock market has, once again, frustrated those who were convinced it was cheap and lived down the expectations of those who asserted it was cheap for good reason," said AJ Bell investment director AJ Bell commented last week.

In comparison to the double-digit returns offered elsewhere, the FTSE 100 offered a paltry 2.4% in 2023.

"However, that gain is supplemented by a dividend yield north of 3.5%, share buybacks and also mergers and acquisitions, so the total cash return will still be in the low double-digit percentage range. That beats inflation, government bond yields and returns on cash. The takeover activity witnessed in the UK again hints that there is value to be found, especially as many deals have been done at a big premium, and as we enter 2024 the UK market may still feature stocks that could appeal to a wide range of investor requirements and risk appetites."

Standout annual performances in the FTSE 100 came from Rolls-Royce, with the jet engine maker's shares tripling in value under the stewardship of its new chief executive Tufan Erginbilhic. Recent returnee to the large-cap index, Marks & Spencer, doubled the value of its shares amid robust trading despite a fairly downbeat consumer environment.

Dragging on the index were miners Anglo American and Fresnillo, losing 40% and 34% respectively. They faced headwinds from falling commodity prices amid a more downbeat assessment for China's economy, the country being a key importer of commodities.

Among its noteworthy stocks for 2024, AJ Bell points to GSK, with its shares closing the year flat, and Legal & General, which fell 0.1% this year.

Pharmaceutical firm GSK said the firm's relatively "static" share price over 2023, leads to a "tempting valuation".

"The relatively predictable demand, high margins and consistent cashflow that can result from a successful drug development model can also appeal at times of economic uncertainty, so GSK may appeal to those investors who fear that an unexpected recession could creep up on the UK equity market next year," AJB's Mould explained.

Meanwhile, life insurance, pensions and investment firm L&G might have its time in the sun, as borrowing costs wind down.

"The lowly valuation on an earnings basis, and forecast 8.5% dividend yield for 2024, offer the potential for capital appreciation and income generation, and management has a plan to increase its shareholder distribution by some 5% a year. Moreover, the balance sheet is strong," Mould noted.

The more domestically-focused FTSE 250 index, adding 2.9% in 2023, proved more resilient than many had expected amid the cost-of-living crisis and stagnant UK economic growth. It shed over 20% in 2022. Meanwhile, the AIM All-Share fell 9.0%, after plunging 31% in 2022.

On the UK front, there is expected to be a general election at some point in 2024. In the meantime, eyes will be on the March budget from Chancellor Jeremy Hunt, with analysts forecasting inheritance tax reform, cuts to fuel duty and income tax, and help for first-time home buyers.

All the while, the UK economy teeters on the edge of recession, as the latest official figures revealed 0.1% quarterly contraction for the third quarter. On a brighter note, inflation cooled more quickly than expected, dropping to 3.9% in November. Still, this remains well above the Bank of England's target of 2%, with Trading Economics forecasts indicating it will only cool to 3.0% by the third quarter of 2024.

The pound finishes the year on a much stronger footing, trading at USD1.2747, slightly higher than USD1.2741 at the London equities close on Thursday.

This is quite a jump from USD1.2054 at the end of 2022, and partly due to the more hawkish positioning of the BoE in comparison to the relatively dovish Fed.

The BoE is expected to begin a slow process of rate cuts from May, at the earliest. Following the Fed's December decision to keep rates on pause, the market rushed to price in at least 150 basis points of interest rate cuts in 2024 beginning from March. This has put selling pressure on the dollar in recent weeks.

The euro traded at USD1.1074, fading slightly from USD1.1078 – but firm on USD1.0686 at the end of 2022. Against the yen, the dollar was quoted at JPY141.42, up versus JPY141.08 – making strong annual gains on JPY131.84, as the Bank of Japan kept its ultra-loose monetary policy in place.

However, market expectations for the path of rates are markedly more dovish than those of the Fed itself. The central bank's latest quarterly dot plot showed that most officials expect rates to be in the range of 4.4% to 4.9% by the end of 2024. The federal funds rate currently stands at a 22-year high of 5.25% to 5.5%, so the dot plot is showing cuts of 100 basis points or less.

On Friday, the Dow Jones Industrial Average, the S&P 500, and the Nasdaq Composite were all called flat.

The Dow is up 14% so far in 2023, the S&P 500 up 25%, and the tech-heavy Nasdaq Composite is up 45%.

"The million-dollar question is what will happen next year. Of course, we don't know, nobody knows, and our crystal balls completely missed the AI rally that marked 2023, yet the general expectation is a cool down in the technology rally, and a rebalancing between the big tech stocks and the S&P493 on narrowing profit lead for the Magnificent 7 compared to the rest of the index in 2024," said Swissquote Bank senior analyst Ipek Ozkardeskaya.

The magnificent seven refers to Microsoft, Apple, Amazon, Meta, Google, Tesla and Nvidia – tech shares which generated almost all of the returns for the S&P 500 and Nasdaq 100.

Nvidia stole the show in 2023, amid the explosion of interest in artificial intelligence. Its shares leapt from USD147 at the beginning of the year to USD495 by the end.

Meanwhile, in commodities, oil prices have operated in a comparatively more stable range this year, after the volatility of 2022 amid the energy crisis prompted by Russia's invasion of Ukraine.

Brent oil was trading at USD77.56 a barrel early Friday, higher than USD78.70 late Thursday. Brent ended 2022 in London at USD83.21, so lost 6.8% over the course of 2023 – its first annual loss since 2020.

Fears of rising oil prices stemming from the conflict in the Middle East have failed to come to pass so far. Further, the waning efficacy of Opec+ alliance production cuts, mounting inventories, and a muted demand outlook continue to weigh on the outlook for oil. London's BP and Shell, which notched gains of 35% and 37% respectively last year, saw a more moderate performance. BP fell 3.7%, while Shell rose 8.6%.

Unlike the oil market, gold had a stellar 2023.

Spot gold has advanced 14% this year. It soared to an all-time record high of USD2,075 an ounce early this month. The precious metal has regained its lustre amid rising hopes that the Fed could pivot to monetary policy easing, and as it benefitted from its safe-haven status, thanks to geopolitical risks.

Dutch bank ING believes that safe-haven demand and the US interest rate outlook will keep gold supported in 2024, expecting the price to remain above the USD2,000 level next year. They even predict a new record high in 2024.

In next week's economic calendar, major financial markets, including the UK, US and Tokyo will remain closed on Monday to mark New Year's Day.

Tuesday brings the latest series of manufacturing PMIs, with services PMIs to follow on Thursday. On Wednesday there will be the US JOLTS and ADP jobs reports and the Federal Reserve's meeting minutes, followed by the closely-watched non-farm payrolls print on Friday.

In the UK corporate calendar, there will be a much-anticipated trading statement from Next on Thursday, which will set the bar for the UK retail sector's festive performance.

By Elizabeth Winter, Alliance News deputy news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
Today 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more
Today 12:22

Sensodyne-maker Haleon to shut UK plant, 435 jobs to go

April 30 (Reuters) - Haleon, the world's largest standalone consumer healthcare firm, will shut its UK production site which makes Sensodyne toothpastes by 2026, leading to 435 job losses, a spokesperson said on Tuesday.

Read more
25 Apr 2024 15:53

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

Read more
24 Apr 2024 14:19

UK earnings, trading statements calendar - next 7 days

Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
Gem Diamonds LtdTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Hummingbird Resources PLCTrading Statement
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
Pinewood Technologies Group PLCFull Year Results
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
Friday 26 April 
Facilities by ADF PLCFull Year Results
Kingspan Group PLCTrading Statement
Loungers PLCTrading Statement
NatWest Group PLC Q1 Results
Pearson PLCTrading Statement
Record PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Taylor Maritime Investments LtdTrading Statement
Monday 29 April 
Beazley PLCTrading Statement
Biome Technologies PLCFull Year Results
Christie Group PLCFull Year Results
Gresham House Energy Storage Fund PLCFull Year Results
Gresham Technologies PLCFull Year Results
Jadestone Energy PLCFull Year Results
Oxford BioMedica PLCFull Year Results
SpaceandPeople PLCFull Year Results
Tuesday 30 April 
Avacta Group PLCFull Year Results
Card Factory PLCFull Year Results
Capital & Regional PLCFull Year Results
Close Brothers Group PLCTrading Statement
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCHalf Year Results
Fadel Partners IncFull Year Results
Glencore PLCTrading Statement
Hargreaves Lansdown PLC Trading Statement
Howden Joinery PLCTrading Statement
HSBC Holdings PLCQ1 Results
Kelso Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Phoenix Spree Deutschland LtdFull Year Results
RBG Holdings PLCFull Year Results
Rotork PLCTrading Statement
Safestore Holdings PLCHalf Year Results
Shield Therapeutics PLCFull Year Results
St James's Place PLCTrading Statement
Strip Tinning Holdings PLCFull Year Results
Whitbread PLCFull Year Results
Wednesday 1 May 
Computacenter PLCTrading Statement
GSK PLCQ1 Results
Haleon PLCTrading Statement
HSS Hire Group PLCFull Year Results
Intelligent Ultrasound Group PLCFull Year Results
Maintel Holdings PLCFull Year Results
Next PLCTrading Statement
Smith & Nephew PLCTrading Statement
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
24 Apr 2024 09:21

GSK's endometrial cancer drug receives FDA approval

(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Jemperli, its drug aimed at treating endometrial cancer.

Read more
24 Apr 2024 09:14

GSK's Jemperli with chemotherapy accepted for priority review by FDA

(Alliance News) - GSK PLC on Wednesday said that the US Food & Drug Administration has accepted a supplemental biologics licence application for Jemperli, when used in combination with chemotherapy.

Read more
17 Apr 2024 08:46

TOP NEWS: GSK hails data on Shingles vaccine and gonorrhoea treatment

(Alliance News) - GSK PLC on Wednesday reported new test data for its shingles vaccine and for a potential new oral treatment for a form of gonorrhoea.

Read more
17 Apr 2024 07:11

GSK posts promising results from gonorrhoea treatment trial

(Sharecast News) - GSK unveiled encouraging outcomes from a pivotal phase three trial on Wednesday, on the potential of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea (GC), amid escalating resistance to current therapies.

Read more
16 Apr 2024 09:17

GSK meningococcal vaccine accepted by US FDA for review

(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA).

Read more
16 Apr 2024 08:59

GSK's latest meningitis vaccine accepted for review by US regulator

(Alliance News) - GSK PLC on Tuesday said it has made progress in the development of its newest candidate, which combines the strengths of two other vaccines in its portfolio into one bacteria-fighting inoculation.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
9 Apr 2024 11:45

Pfizer RSV shot meets goals in trial of high-risk adults under age 60

April 9 (Reuters) - Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60 similar to that in older adults, for whom the shot is already approved.

Read more
8 Apr 2024 09:13

LONDON BROKER RATINGS: Wizz Air raised; HSBC cuts Rentokil to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
4 Apr 2024 13:08

UK dividends calendar - next 7 days

Friday 5 April 
BBGI Global Infrastructure SAdividend payment date
Molten Ventures PLCdividend payment date
Pennon Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
Regional REIT Ltddividend payment date
Rights & Issues Investment Trust PLCdividend payment date
Sylvania Platinum Ltddividend payment date
Titon Holdings PLCdividend payment date
Triple Point Energy Transition PLCdividend payment date
Monday 8 April 
Alumasc Group PLCdividend payment date
LondonMetric Property PLCdividend payment date
Redrow PLCdividend payment date
Tuesday 9 April 
CT Global Managed Portfolio Trust PLCdividend payment date
Downing Strategic Micro-Cap Investment Trust PLCdividend payment date
Dunelm Group PLCspecial dividend payment date
Hays PLCdividend payment date
Renishaw PLCdividend payment date
Safestore Holdings PLCdividend payment date
Wednesday 10 April 
Assura PLCdividend payment date
Primorus Investments PLCspecial dividend payment date
Wilmington PLCdividend payment date
Thursday 11 April 
Amedeo Air Four Plus Ltdex-dividend payment date
Athelney Trust PLCdividend payment date
Aviva PLCex-dividend payment date
Balanced Commercial Property Trust Ltdex-dividend payment date
Barratt Developments PLCex-dividend payment date
Begbies Traynor Group PLCex-dividend payment date
Bioventix PLCex-dividend payment date
Blackfinch Spring VCT PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
Caledonia Mining Corpex-dividend payment date
Capital & Regional PLCex-dividend payment date
Chesnara PLCex-dividend payment date
Colefax Group PLCdividend payment date
CT Private Equity Trust PLCex-dividend payment date
Downing Strategic Micro-Cap Investements Trust PLCex-dividend payment date
Driver Group PLCdividend payment date
F&C Investment Trust PLCex-dividend payment date
Foxtons Group PLCex-dividend payment date
Grafton Group PLCex-dividend payment date
GSK PLCdividend payment date
Harbour Energy PLCex-dividend payment date
Hargreaves Services PLCdividend payment date
Howden Joinery Group PLCex-dividend payment date
Hunting PLCex-dividend payment date
i3 Energy PLCex-dividend payment date
International Personal Finance PLCex-dividend payment date
International Public Partnerships Ltdex-dividend payment date
ITV PLCex-dividend payment date
Johnson Service Group PLCex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
JPMorgan Japan Small Cap Growth & Income PLCex-dividend payment date
Just Group PLCex-dividend payment date
Kenmare Resources PLCex-dividend payment date
Kerry Group PLCex-dividend payment date
Kings Arms Yard VCT PLCex-dividend payment date
Law Debenture Corp PLCdividend payment date
Lloyds Banking Group PLCex-dividend payment date
Lowland Investment Cos PLCex-dividend payment date
Luceco PLCex-dividend payment date
Man Group PLCex-dividend payment date
Manchester & London Investement Trust PLCex-dividend payment date
Marble Point Loan Financing Ltdex-dividend payment date
Mercantile Investment Trust PLCex-dividend payment date
Mobius Investment Trust PLCex-dividend payment date
MTI Wireless Edge Ltddividend payment date
North American Income Trust PLCex-dividend payment date
Northamber PLCex-dividend payment date
Octopus Apollo VCT PLCex-dividend payment date
Phoenix Group Holdings PLCex-dividend payment date
Reckitt Benckiser Group PLCex-dividend payment date
Ricardo PLCdividend payment date
Savills PLCex-dividend payment date
Schroder Asian Total Return Investment Cos PLCex-dividend payment date
Schroder European Real Estate Investment Trust PLCex-dividend payment date
Scottish American Investment Cos PLCdividend payment date
Smurfit Kappa Group PLCex-dividend payment date
Softcat PLCex-dividend payment date
Somero Enterprises Incex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Synectics PLCex-dividend payment date
TP ICAP Group PLCex-dividend payment date
Trifast PLCdividend payment date
TT Electronics PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.